HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $50

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a 'Buy' rating on Genmab (NASDAQ: GMAB) and increased the price target from $40 to $50. This adjustment reflects a positive outlook for the company's performance in the market.